Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Microsporidiosis Indication Strategy Report 2026: Methionine aminopeptidase, Trials and Deals
3 August 2026
2026 Microsporidiosis indication strategy covering epidemiology, Methionine aminopeptidase biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Toxoplasmic encephalitis Indication Strategy Report 2026: DHFR, Trials and Deals
3 August 2026
2026 Toxoplasmic encephalitis indication strategy covering epidemiology, DHFR biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Relapsing fever Indication Strategy Report 2026: Vmp, Trials and Deals
3 August 2026
2026 Relapsing fever indication strategy covering epidemiology, Vmp biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Plague Indication Strategy Report 2026: F1 antigen, Trials and Deals
3 August 2026
2026 Plague indication strategy covering epidemiology, F1 antigen biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Dengue hemorrhagic fever Indication Strategy Report 2026: NS5, Trials and Deals
3 August 2026
2026 Dengue hemorrhagic fever indication strategy covering epidemiology, NS5 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
West Nile neuroinvasive disease Indication Strategy Report 2026: NS5, Trials and Deals
3 August 2026
2026 West Nile neuroinvasive disease indication strategy covering epidemiology, NS5 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Rift Valley fever Indication Strategy Report 2026: Viral polymerase, Trials and Deals
3 August 2026
2026 Rift Valley fever indication strategy covering epidemiology, Viral polymerase biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Chikungunya fever Indication Strategy Report 2026: nsP2, Trials and Deals
3 August 2026
2026 Chikungunya fever indication strategy covering epidemiology, nsP2 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Oropouche fever Indication Strategy Report 2026: Viral polymerase, Trials and Deals
3 August 2026
2026 Oropouche fever indication strategy covering epidemiology, Viral polymerase biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Severe fever with thrombocytopenia syndrome Indication Strategy Report 2026: Viral polymerase, Trials and Deals
3 August 2026
2026 Severe fever with thrombocytopenia syndrome indication strategy covering epidemiology, Viral polymerase biology, active trials, transactions, unmet need,…
Latest Hotspot
8 min read
Progressive multifocal leukoencephalopathy Indication Strategy Report 2026: VP1, Trials and Deals
3 August 2026
2026 Progressive multifocal leukoencephalopathy indication strategy covering epidemiology, VP1 biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Parainfluenza virus infection Indication Strategy Report 2026: HN protein, Trials and Deals
3 August 2026
2026 Parainfluenza virus infection indication strategy covering epidemiology, HN protein biology, active trials, transactions, unmet need, competition and market…